Pradaxa® (dabigatran etexilate) receives final NICE recommendation for stroke prevention in atrial fibrillation in the UK
19 March 2012 | By NICE
Pradaxa® must now be made available for use by the UK National Health Service (NHS)...
List view / Grid view
19 March 2012 | By NICE
Pradaxa® must now be made available for use by the UK National Health Service (NHS)...
20 December 2011 | By Bayer HealthCare
The only new oral anticoagulant approved in three indications across all 27 EU member states...
27 October 2011 | By Boehringer Ingelheim
Update across Europe on Pradaxa®...
6 September 2011 | By Bayer
Study to be reviewed by the FDA Cardiovascular and Renal Drugs Advisory Committee...
New data from two RE-LY® trial subgroup analyses show that dabigatran etexilate 150mg bid consistently reduces the risk of stroke in atrial fibrillation (AF) compared to well-controlled warfarin, irrespective of whether patients use antiplatelet [1] or other concomitant therapies, such as the anti-arrhythmics amiodarone or verapamil. [2] The relative benefits…
10 February 2011 | By Pfizer
Bristol-Myers Squibb Company and Pfizer Inc. announce the publication of their AVERROES study of apixaban in The New England Journal of Medicine...